Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia, Schizoaffective Disorder
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
- Trial name
- NCT04512066
- Testing
- RO6889450, Risperidone
- Where
- 40 sites in United States, Japan and 2 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Hallucinations
Transcranial Magnetic Stimulation for "Voices"
This study will determine the efficacy of MRI-guided transcranial magnetic stimulation (TMS)in reducing "voices" and other symptoms experienced by people with schizophrenia and schizoaffective disorder.
- Trial name
- NCT00308997
- Testing
- 1-hertz Repetitive Transcranial Magnetic Stimulation, Active 1-Hertz Repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Yale University
Schizophrenia
A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia
The primary objectives of the study is to confirm if the efficacy of IM olanzapine in patients with schizophrenia is greater than IM placebo by comparing changes from baseline to 2 hours post first IM injection of agitation.
- Trial name
- NCT00640510
- Testing
- Rapid Acting Intramuscular Olanzapine, Isotonic sodium chloride solution
- Where
- 11 sites in Japan
- Volunteers
- 34 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin
This study supplements patients' current medications with Pravastatin, a cholesterol-lowering medication, to try to improve residual symptoms of schizophrenia, and also to improve cognitive functioning.
- Trial name
- NCT00177580
- Testing
- Pravastatin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Schizoaffective Disorder
Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
To evaluate the efficacy, safety and tolerability of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder with risperidone as an active control.
- Trial name
- NCT00283179
- Testing
- Aripiprazole, Risperidone
- Where
- Taiwan
- Volunteers
- 83 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Schizophrenia
Effect of Psychoeducation -Based Motivational Interviewing on Knowledge and Hope in Schizophrenia
This study aimed to examine the effect of a psychoeducation-based motivational interviewing intervention on schizophrenia-related knowledge and hope levels among patients diagnosed with schizophrenia.
- Trial name
- NCT07365982
- Testing
- Psychoeducation-Based Motivational Interviewing
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Büşra Taşkıner
Schizophrenia, Schizotypal and Delusional Disorders
The Efficacy of Using a Smartphone App to Support Shared Decision Making in People With a Diagnosis of Schizophrenia
This study investigates the effects of using a smartphone app to support shared decision making (SDM) for people with schizophrenia-spectrum disorders in an outpatient treatment setting.
- Trial name
- NCT03554655
- Testing
- Momentum app
- Where
- 7 sites in Denmark
- Volunteers
- 194 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Major Depressive Disorder, Psychotic Disorders
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00130676
- Testing
- Mifepristone
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Corcept Therapeutics
Schizophrenia
The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia
The purpose of this study is to examine the long-term economic, functional and clinical outcomes in schizophrenia patients who require a change in antipsychotic treatment, and are changed to either paliperidone extended release…
- Trial name
- POST (NCT00488891)
- Testing
- Paliperidone ER, Atypical antipsychotics (AAP)
- Volunteers
- 43 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Schizophrenia, Extrapyramidal Syndrome
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism
We initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications.
- Trial name
- NCT00331825
- Testing
- Risperidone and Olanzapine
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Tardive Dyskinesia
Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia
The aim of the study was to evaluate the efficacy, safety, and cognitive function of transcranial direct current stimulation (tDCS) in chronic schizophrenia patients with tardive dyskinesia (TD).
- Trial name
- NCT03497013
- Testing
- Active tDCS
- Where
- 2 sites in China
- Volunteers
- 64 people
- Sponsor
- Suzhou Psychiatric Hospital
Bipolar Disorder, Schizophrenia
Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine
The purpose of this study is to determine if taking green tea capsules can help prevent weight gain in patients that start therapy with Zyprexa® (olanzapine).
- Trial name
- NCT00934908
- Testing
- Green Tea
- Where
- United States
- Sponsor
- Medical University of South Carolina
Schizophrenia
Digital Voice Analysis in Patients With Schizophrenia
There is a differences in voice frequency of schizophrenic patients compared to patients with other mental diseases and compared to mentally healthy people.
- Trial name
- NCT00524979
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BeerYaakov Mental Health Center
Schizophrenia
Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy (effectiveness of drug) and safety of the antipsychotic paliperidone ER compared to another antipsychotic, quetiapine, and to placebo in patients who are acutely ill with…
- Trial name
- NCT00334126
- Volunteers
- 399 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
- Trial name
- NCT00857818
- Testing
- Aripiprazole, Oanzapine, risperidone, or quetiapine
- Where
- 14 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
The Effect of a Community-based LAT-treated Management Model on the Violence Risk of Patients With Schizophrenia
This is a 49 weeks open-label randomized controlled study. Patients with schizophrenia and violence risk will be enrolled in the study.
- Trial name
- NCT03434210
- Testing
- LAT-treated Community Model, care as usual
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Yi Li MD, PhD
Parkinson's Disease, Psychoses
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
- Trial name
- NCT00095810
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizophreniform Disorders
Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early Schizophrenia
This study aims to test the hypothesis that addition of Individual Placement and Support (IPS) and/or Cognitive Remediation Therapy (CRT) in addition to treatment as usual in patients with early psychosis will be feasible and…
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Psychosis
- Trial name
- NCT03974620
- Testing
- Individual Placement and Support, Cognitive Remediation Therapy
- Volunteers
- 120 people
- Sponsor
- Pakistan Institute of Living and Learning
Schizophrenia, Psychotic Disorders
Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis
The purpose of this research study is to see how well patients in an early phase of their illness respond to treatment and whether this depends on how well they functioned socially, academically and vocationally before becoming…
- Conditions
- Schizophrenia, Psychotic Disorders, Schizoaffective Disorder
- Trial name
- NCT00369239
- Testing
- risperidone long acting injectable
- Volunteers
- 303 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Auditory Hallucinations in Patients With Schizophrenic Disorders
High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia : a Randomized Controlled Study
Background: Repetitive transcranial magnetic stimulation (rTMS) is a recent therapeutic which has demonstrated its efficacy in the treatment of auditory hallucinations in patients with schizophrenic disorders.
- Trial name
- TMS-Hz (NCT01022489)
- Testing
- Transcranial magnetic stimulation: rTMS
- Where
- France
- Volunteers
- 72 people
- Sponsor
- University Hospital, Caen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.